Cargando…

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines

Objectives: Underlying mechanisms regulating angiogenesis in ovarian cancer have not been completely elucidated. Evidence suggests that the TP53 tumor suppressor pathway and tumor microenvironment play integral roles. We utilized microarray technology to study the interaction between TP53 mutational...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Brittany Anne, Rubatt, Jennifer M., Corcoran, David L., Teoh, Deanna K., Bernardini, Marcus Q., Grace, Lisa A., Soper, William John, Berchuck, Andrew, Siamakpour-Reihani, Sharareh, Chen, Wei, Owzar, Kouros, Murphy, Susan K., Secord, Angeles Alvarez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4064453/ https://www.ncbi.nlm.nih.gov/pubmed/24999452 http://dx.doi.org/10.3389/fonc.2014.00163

Ejemplares similares

Expression signatures of TP53 mutations in serous ovarian cancers
por: Bernardini, Marcus Q, et al.
Publicado: (2010)

TP53 Status is Associated with Thrombospondin1 Expression In vitro
por: Alvarez Secord, Angeles, et al.
Publicado: (2013)

H(2)O(2)-Driven Anticancer Activity of Mn Porphyrins and the Underlying Molecular Pathways
por: Batinic-Haberle, Ines, et al.
Publicado: (2021)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer
por: Davidson, Brittany A, et al.
Publicado: (2014)

DNA-Damage-Induced Alternative Splicing of p53
por: Chen, Jing, et al.
Publicado: (2021)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

TP53: an oncogene in disguise
por: Soussi, T, et al.
Publicado: (2015)

Next Generation Distributed Computing for Cancer Research
por: Agarwal, Pankaj, et al.
Publicado: (2015)

Molecular characterization of AML‐MRC reveals TP53 mutation as an adverse prognostic factor irrespective of MRC‐defining criteria, TP53 allelic state, or TP53 variant allele frequency
por: Zhao, Davidson, et al.
Publicado: (2022)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Associations between lymphovascular space invasion, nodal recurrence, and survival in patients with surgical stage I endometrioid endometrial adenocarcinoma
por: Veade, Ashley E., et al.
Publicado: (2019)

TP53 and TP53-associated genes are correlated with the prognosis of paediatric neuroblastoma
por: Wang, Haiwei, et al.
Publicado: (2022)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer
por: Ignacio, Rosa Mistica C., et al.
Publicado: (2018)

S127: DELTATP73 IMPOSES TP53 MUTANT-LIKE PHENOTYPES INCLUDING DRUG RESISTANCE AND POOR PROGNOSIS ON TP53-WILD TYPE ACUTE MYELOID LEUKEMIA.
por: Pereira-Martins, Diego A, et al.
Publicado: (2023)

Optimisation of TP53 reporters by systematic dissection of synthetic TP53 response elements
por: Trauernicht, Max, et al.
Publicado: (2023)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Kevetrin induces apoptosis in TP53 wild-type and mutant acute myeloid leukemia cells
por: Napolitano, Roberta, et al.
Publicado: (2020)

The TP53 fertility network
por: Paskulin, Diego d’Avila, et al.
Publicado: (2012)

TP53 in Myelodysplastic Syndromes
por: Jiang, Yan, et al.
Publicado: (2021)

Studies of TP53 haplotypes in relation to LOH and TP53 mutations in breast cancer patients
por: Langerød, A, et al.
Publicado: (2000)

Mapping eQTL by leveraging multiple tissues and DNA methylation
por: Acharya, Chaitanya R., et al.
Publicado: (2017)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

Comparison of Modules of Wild Type and Mutant Huntingtin and TP53 Protein Interaction Networks: Implications in Biological Processes and Functions
por: Basu, Mahashweta, et al.
Publicado: (2013)

Redox-sensitive TP53INP1 SUMOylation as an oxidative stress sensor to activate TP53
por: Bonacci, Thomas, et al.
Publicado: (2014)

TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes
por: Yabe, Mariko, et al.
Publicado: (2021)

TP53_PROF: a machine learning model to predict impact of missense mutations in TP53
por: Ben-Cohen, Gil, et al.
Publicado: (2022)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

MBRS-21. CLINICAL AGGRESSIVENESS OF TP53-WILD TYPE SONIC HEDGEHOG MEDULLOBLASTOMA WITH MYCN AMPLIFICATION
por: Mitani, Yuichi, et al.
Publicado: (2020)

The Role of Calcineurin/NFAT in SFRP2 Induced Angiogenesis—A Rationale for Breast Cancer Treatment with the Calcineurin Inhibitor Tacrolimus
por: Siamakpour-Reihani, Sharareh, et al.
Publicado: (2011)

The Consequence of Oncomorphic TP53 Mutations in Ovarian Cancer
por: Brachova, Pavla, et al.
Publicado: (2013)

Updates from the TP53 universe
por: Pentimalli, Francesca
Publicado: (2018)

TP53 in Biology and Treatment of Osteosarcoma
por: Synoradzki, Kamil Jozef, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_sn2nrmekc869setmp423jgkg46